About Transmembrane protein 184A
Transmembrane protein 184A (TMEM184A) is a protein
from Homo sapiens identified by UniProt accession
Q6ZMB5, 413 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | Transmembrane protein 184A |
| UniProt accession | Q6ZMB5 |
| Gene | TMEM184A |
| Organism | Homo sapiens |
| Length | 413 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.41
- body height · score 0.31
- blood protein measurement · score 0.09
- appendicular lean mass · score 0.09
- serum gamma-glutamyl transferase measurement · score 0.09
- age at menarche · score 0.05
- bone density · score 0.04
- urate measurement · score 0.04
- sex hormone-binding globulin measurement · score 0.03
- age at first sexual intercourse measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6ZMB5-F1 | alphafold | PREDICTED | 72.19 | — |
Amino-acid sequence (413 residues)
MSNVSGILET AGVPLVSANW PQPSPPPAVP AGPQMDHMGN SSQGAPWLFL TSALARGVSG IFVWTALVLT CHQIYLHLRS YTVPQEQRYI IRLLLIVPIY AFDSWLSLLL LGDHQYYVYF DSVRDCYEAF VIYSFLSLCF QYLGGEGAIM AEIRGKPIKS SCLYGTCCLR GMTYSIGFLR FCKQATLQFC LVKPVMAVTT IILQAFGKYH DGDFNVRSGY LYVTLIYNAS VSLALYALFL FYFTTRELLR PFQPVLKFLT IKAVIFLSFW QGLLLAILER CGVIPEVETS GGNKLGAGTL AAGYQNFIIC VEMLFASVAL RYAFPCQVYA EKKENSPAPP APMQSISSGI RETVSPQDIV QDAIHNFSPA YQHYTQQATH EAPRPGTHPS GGSGGSRKSR SLEKRMLIPS EDL
Explore Transmembrane protein 184A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets